ft 25 jan 94 roch find new mean post valium world highli valu drug group roch back big swiss drug group stage remark recoveri head field follow long sever case post valium depress public last week ft 500 rank europ top compani reveal roch risen becom third largest market valu dollar 35 7bn pound 24bn exceed british telecom royal dutch shell follow anoth mileston last septemb group surpass merck us becom world highli valu drug group rank held sinc peak tranquilis boom late 1960 roch still rememb prosecut british former employe expos vitamin price fix practic 1973 achiev comeback time profit prospect big pharmaceut group suffer govern move rein healthcar spend roch sale jump 11 per cent sfr14 3bn pound 6 5bn last year third success year doubl digit growth net incom estim sfr2 54bn third 1992 level investor believ group sever year doubl digit profit growth store bid share 18 time estim 1994 earn well ahead lead drug group main reason optim roch chock full pipelin new product group extraordinarili strong balanc sheet cash secur believ total sfr2bn also much valu time pressur competitor might yield lifetim acquisit opportun long way 1978 mr paul sacher orchestra conductor music philanthropist lead control hoffmann la roch famili interest group call mr fritz gerber promin swiss industrialist becom execut chairman mr sacher sens phenomen success valium librium undermin group dynam impend expiri patent tranquilis threaten futur mr gerber enter find group profit product tranquilis research depart live well noth come along take 10 year bring new drug market deal glaxo wherebi british group would use roch larg sale forc us sell new anti ulcer drug zantac also brought inject antibiot develop hous reject roch r amp manag uninterest rocephin hit market right time use hospit becom widespread day applic save staff time money still roch top sell product two move alon probabl save group traumat surgeri sinc patient rebuilt dynam r amp system wide varieti product market pipelin never depend blockbust like valium roch offici promis roch product line impress investor aim mainli hospit rather retail chemist hospit market long tough profession sell group suffer less competitor squeez retail drug price gerber admit potenti price rise even keep pace inflat sever limit forese futur group reli even innov product increasingli aim effort intract diseas reward although difficult achiev could greatest lead product eas chemotherapi effect leukaemia depress parkinson diseas epilepsi rheumat heart failur aid gerber sharpen roch divis sell unpromis busi agricultur chemic strengthen other acquisit counter medicin divis propel intern competit size dollar 821m purchas nichola maker aspro renni 1991 flavour fragranc divis becam number two sector acquisit fritzsch dodg olcott 1990 merger givaudan rour follow year investor especi excit two biotechnolog ventur three year ago roch bought 60 per cent stake genentech california dollar 2bn genentech produc wide use genet engin drug activas combat blood clot heart attack victim approv pulmozym treat cystic fibrosi prospect eas bronchiti genentech put roch forefront genet engin begin challeng chemistri sourc drug innov 1991 roch paid dollar 300m us compani diagnost technolog polymeras chain reaction pcr analys blood variou diseas sinc spent sever hundr million dollar get pcr market form pcr kit technician test hiv viru thought caus aid matter hour rather sever week requir former method greater accuraci group launch autom pcr system medium size laboratori test eight diseas alreadi press fill order spite aggress invest roch amass immens cash pile gerber say strong balanc sheet enabl group take big risk genentech pcr purchas would never courag borrow say group financi deal also provid healthi profit stream mr henri meier financ director refus reveal tactic detail insist group invest top rate secur reject alleg invest share manipul market secret arrog roch becom much investor consum friendli still mysteri concern futur control especi mr sacher 88 vote share bearer form thing clear famili own major gerber simpli say iron clad pool arrang among famili member maintain outright major vote share well next centuri roch sale divis 1992 1993 sfr sfr chang pharma 6 886 7 813 13 vitamin amp fine chemic 3 070 3 275 7 diagnost 1 561 1 720 10 fragranc amp flavor 1 352 1 436 6 other 84 87 4 total sale 12 953 14 331 11